Raymond James Financial Services Advisors, Inc. Halozyme Therapeutics, Inc. Transaction History
Raymond James Financial Services Advisors, Inc.
- $73.5 Billion
- Q3 2024
A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 16,353 shares of HALO stock, worth $933,756. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,353Holding current value
$933,756% of portfolio
0.0%Shares
8 transactions
Others Institutions Holding HALO
# of Institutions
536Shares Held
123MCall Options Held
294KPut Options Held
169K-
Black Rock Inc. New York, NY17.6MShares$1.01 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$736 Million0.01% of portfolio
-
State Street Corp Boston, MA6.63MShares$379 Million0.02% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.06MShares$232 Million5.07% of portfolio
-
Alliancebernstein L.P. New York, NY3.41MShares$195 Million0.07% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.95B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...